HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Q: How long will it take to read this news story?

The story "HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules" has 1011 words across 32 sentences, which will take approximately 5 - 9 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules" was covered 5 days ago by Benzinga, a news publisher based in United States.

Q: How trustworthy is 'Benzinga' news outlet?

Benzinga is a fully independent (privately-owned) news outlet established in 2010 that covers mostly investing and business news. The outlet is headquartered in United States and publishes an average of 0 news stories per day. It's most recent story was published 1 days ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23787746</li><li>URL: https://beamstart.com/news/hcw-biologics-announces-pricing-of-17324326749358</li></ul>

Benzinga Logo Benzinga 5d ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules - Benzinga

Quick Summary:

MIRAMAR, Fla., Nov.18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc.("HCWB" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced above market under Nasdaq rules.

The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants is $1.03.

The shares of common stock (or pre-funded warrants in lieu thereof) are being offered pursuant to a shelf registration statement on Form S-3 (File No.333-266991), which was declared effective by the U.S.